Should the Israeli government raise taxes on citizens and corporations, that might prompt the nation's companies -- such as Check Point Software Technologies (CHKP) and Nice Systems (NICE) -- to move.
"We rate TEVA PHARMACEUTICALS (TEVA) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- TEVA's revenue growth has slightly outpaced the industry average of 4.6%. Since the same quarter one year prior, revenues slightly increased by 2.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Powered by its strong earnings growth of 264.15% and other important driving factors, this stock has surged by 32.92% over the past year, outperforming the rise in the S&P 500 Index during the same period. Turning to the future, naturally, any stock can fall in a major bear market. However, in almost any other environment, the stock should continue to move higher despite the fact that it has already enjoyed nice gains in the past year.
- The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 265.5% when compared to the same quarter one year prior, rising from -$452.00 million to $748.00 million.
- Net operating cash flow has increased to $1,053.00 million or 20.34% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of -18.54%.
- You can view the full analysis from the report here: TEVA Ratings Report